APACE

  • Research type

    Research Study

  • Full title

    A feasibility study evaluating of the use of accelerometers to capture physical activity levels in cancer patients on early phase clinical trials.

  • IRAS ID

    311863

  • Contact name

    Stacey Body

  • Contact email

    fbmhethics@manchester.ac.uk

  • Sponsor organisation

    The University of Manchester

  • Duration of Study in the UK

    1 years, 0 months, 0 days

  • Research summary

    Increased physical activity has been shown to improve outcomes for cancer patients, however the measure of activity is highly variable and understudied in cancer patients on early phase clinical trials where activity is used as a criteria for eligibility. Additionally, more than half of cancer patients experience fatigue at some point in their treatment with exercise and psychosocial interventions currently recommended as interventions. Therefore, it is important to be able to more accurately measure activity and fatigue in cancer patients to ensure adequate intervention, management and appropriate access to treatment.

    This proposal is a non-interventional feasibility study designed to collect activity and sleep data from patients with advanced cancer newly enrolled in early phase clinical trials. The data will be collected over a 5–6 week period using a wearable accelerometer device. This study will be conducted concurrently with the early phase trial related activities/treatment and will have no impact on a patient’s clinical pathway.
    Data generated from the study will be used to evaluate the feasibility of collecting activity and sleep data from patients with advanced cancer on early phase clinical trials.

    In this study, participants in the UK will be able to opt-in to using eNutri, a web-based graphical food frequency questionnaire (FFQ), and provide feedback on its usability. The output of eNUTRI will help us understand if there is a use for eNutri in cancer care environments for a range of purposes such as providing nutritional support for cancer patients, and exploring drug-nutrient interactions on the patient outcome.

  • REC name

    North West - Liverpool Central Research Ethics Committee

  • REC reference

    23/NW/0023

  • Date of REC Opinion

    16 Jan 2023

  • REC opinion

    Favourable Opinion